Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Paradigm Biocapital Advisors LP (CIK 1855655) reported $4.89B across 33 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: ACLX ($663.0M, 13.55%), RVMD ($647.3M, 13.23%), NUVL ($545.5M, 11.15%), PCVX ($278.5M, 5.69%), EWTX ($232.0M, 4.74%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ACLX | ARCELLX INC | $663.0M | 13.55% | 5.8M | Added |
| 2 | RVMD | REVOLUTION MEDICINES INC | $647.3M | 13.23% | 6.7M | Added |
| 3 | NUVL | NUVALENT INC | $545.5M | 11.15% | 5.3M | Added |
| 4 | PCVX | VAXCYTE INC | $278.5M | 5.69% | 4.8M | Added |
| 5 | EWTX | EDGEWISE THERAPEUTICS INC | $232.0M | 4.74% | 7.4M | Added |
| 6 | GMAB | GENMAB A/S | $213.8M | 4.37% | 8.0M | Added |
| 7 | INSM | INSMED INC | $205.1M | 4.19% | 1.3M | New |
| 8 | TARS | TARSUS PHARMACEUTICALS INC | $179.7M | 3.67% | 2.6M | Hold |
| 9 | BLTE | BELITE BIO INC | $177.7M | 3.63% | 1.1M | New |
| 10 | ERAS | ERASCA INC | $168.2M | 3.44% | 10.4M | Trimmed |
| 11 | CNTA | CENTESSA PHARMACEUTICALS PLC | $142.0M | 2.90% | 3.6M | New |
| 12 | OLMA | OLEMA PHARMACEUTICALS INC | $119.6M | 2.44% | 8.0M | Added |
| 13 | TERN | TERNS PHARMACEUTICALS INC | $116.9M | 2.39% | 2.2M | Added |
| 14 | ORKA | ORUKA THERAPEUTICS INC | $113.8M | 2.33% | 2.3M | Added |
| 15 | APGE | APOGEE THERAPEUTICS INC | $113.5M | 2.32% | 1.3M | Added |
| 16 | SYRE | SPYRE THERAPEUTICS INC | $98.7M | 2.02% | 2.0M | Added |
| 17 | CYTK | CYTOKINETICS INC | $97.6M | 1.99% | 1.5M | New |
| 18 | ABVX | ABIVAX SA | $86.0M | 1.76% | 772,473 | Trimmed |
| 19 | TNGX | TANGO THERAPEUTICS INC | $83.9M | 1.71% | 4.0M | New |
| 20 | MAZE | MAZE THERAPEUTICS INC | $81.9M | 1.67% | 2.7M | New |
| 21 | TYRA | TYRA BIOSCIENCES INC | $78.7M | 1.61% | 2.1M | New |
| 22 | VRDN | VIRIDIAN THERAPEUTICS INC | $61.6M | 1.26% | 3.1M | Added |
| 23 | SRRK | SCHOLAR ROCK HLDG CORP | $60.3M | 1.23% | 1.2M | Trimmed |
| 24 | MIRM | MIRUM PHARMACEUTICALS INC | $57.7M | 1.18% | 625,000 | New |
| 25 | EYPT | EYEPOINT INC | $40.5M | 0.83% | 3.1M | Trimmed |
Source: SEC Form 13F filings · as of 2026-03-31